COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs | Annals of the Rheumatic Diseases

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

This article has a Reply. Please see:

COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: ‘Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials – a real-world district general hospital experience’ by Khan et al, ‘Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al’ by Andreica et al and ‘COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs’ by Ansarin et al - October 01, 2022

Correspondence

COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs

Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Ansarin K, Taghizadieh A, Safiri S, et al

COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs

Annals of the Rheumatic Diseases 2022;81:e190.